Key Takeaway: Kalaris has reported its financial results for Q2 2026, highlighting ongoing patient dosing in the Phase 1b/2 study of TH103. The company anticipates preliminary data in the first half of 2027 and is on track to initiate Phase 3 clinical trials by the end of 2027. As of June 30, 2026, Kalaris holds $93.5 million in cash and equivalents to support its operations.
Market Sentiment Analysis
POSITIVE FACTORS
Ongoing patient dosing in Phase 1b/2 study of TH103.
Preliminary data expected in 1H 2027.
Phase 3 clinical trials on track for initiation by year-end 2027.
$93.5 million in cash expected to fund operations.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~24 mo
Minimal dilution risk
Lead asset
Multivirus-specific T cells Dose Level 1
Phase 1 · Viral Infection
Full Press Release Details
Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in cash, cash equivalents and marketable securities as of June 30, 2026 is expected to fund operations
Frequently Asked Questions
What is the status of the TH103 study?
Patient dosing is ongoing in the Phase 1b/2 study of TH103.
When is preliminary data for TH103 expected?
Preliminary data for TH103 is anticipated in the first half of 2027.
What are Kalaris's plans for Phase 3 trials?
Kalaris plans to initiate Phase 3 clinical trials by the end of 2027.
How much cash does Kalaris have as of June 30, 2026?
Kalaris has $93.5 million in cash, cash equivalents, and marketable securities.